A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study

BACKGROUND: Intermittent androgen suppression (1) is an increasingly popular treatment option for hormone sensitive prostate cancer. Based on previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor (VEGFR) using pazopanib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, James E., Karrison, Theodore, Chatta, Gurkamal, Hussain, Maha, Shevrin, Daniel, Szmulewitz, Russell Z., O’Donnell, Peter H., Stadler, Walter M., Posadas, Edwin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312616/
https://www.ncbi.nlm.nih.gov/pubmed/22006050
http://dx.doi.org/10.1038/pcan.2011.49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312616/
https://www.ncbi.nlm.nih.gov/pubmed/22006050
http://dx.doi.org/10.1038/pcan.2011.49

Ejemplares similares